KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled Water or Saline at High Volumes After Pancreatic Resection for Pancreatic Ductal Adenocarcinoma. PMID 35661956 · Ann Surg Oncol · 2022-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin. PMID 35657463 · Ann Surg Oncol · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. PMID 35648041 · Leuk Lymphoma · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study. PMID 35636696 · J Thorac Oncol · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group. PMID 35634931 · Eur J Haematol · 2022-Sep The record describes a randomized, oncology (AML) trial with a drug intervention and primary time-to-event endpoints (OS, RFS), and is an original result report. However, the abstract and provided metadata do not explicitly state the trial phase as Phase III/IIIb or Phase II/III. The deterministic review flags 'phase3_evidence_unclear'. Therefore, the criterion 'phase3_or_definitive' cannot be established from the provided information, making the record ineligible per the strict instruction to not infer missing metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and validation of a nomogram to predict survival for advanced male breast cancer. PMID 35618959 · Andrologia · 2022-Sep The record is a prognostic nomogram study based on a retrospective SEER database cohort, not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention. The 'Randomized Controlled Trial' publication type refers to the random split of patients for model development/validation, not a therapeutic trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial. PMID 35552930 · Ann Surg Oncol · 2022-Sep The trial is a randomized, oncology study with time-to-event endpoints (OS, recurrence) and reports primary results. However, it lacks a drug-containing intervention (comparing surgical techniques) and does not explicitly confirm Phase III/IIIb or Phase II/III status in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial. PMID 35549312 · J Urol · 2022-Sep The record describes a single-arm, prospective, diagnostic accuracy study for a urine biomarker test in upper tract urothelial carcinoma. It is not a randomized trial of a drug intervention with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Retzius-Sparing vs Modified Anatomical Structure Preserving and Retzius-Repairing Robotic-Assisted Radical Prostatectomy: A Prospective Randomized Comparison on Functional Outcomes with a 1-Year Follow-Up. PMID 35546454 · J Endourol · 2022-Sep 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Harvest for Health, a Randomized Controlled Trial Testing a Home-Based, Vegetable Gardening Intervention Among Older Cancer Survivors Across Alabama: An Analysis of Accrual and Modifications Made in Intervention Delivery and Assessment During COVID-19. PMID 35533876 · J Acad Nutr Diet · 2022-Sep This is a randomized controlled trial in cancer survivors, but it is not a Phase III drug trial. The intervention is a non-drug lifestyle intervention (vegetable gardening), and the primary endpoint is a composite of dietary, activity, and functioning measures, not a time-to-event endpoint like OS or PFS. The report focuses on accrual and COVID-19 modifications, not final efficacy results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. PMID 35505251 · Br J Cancer · 2022-Sep The study is an observational analysis of anti-epileptic drug use within a prostate cancer screening trial. While it is oncology, human, randomized (underlying trial), and reports a time-to-event endpoint with an HR, it does not meet the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention. The 'drug_intervention' is not a randomized intervention in the trial, and the phase is not established as definitive for a drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. PMID 35503379 · Eur J Nucl Med Mol Imaging · 2022-Sep The study is a randomized trial in oncology with drug intervention and time-to-event endpoints, but the trial phase is not explicitly reported as Phase III/IIIb or Phase II/III in the provided metadata. The abstract describes it as a 'prospective, randomised, single-centre study' without a specific phase label. Therefore, it does not meet the explicit phase criterion required for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. PMID 35491363 · Eur J Surg Oncol · 2022-Sep This record is a meta-analysis/trial sequential analysis of multiple randomized controlled trials, not an original report of a single Phase III/IIIb or Phase II/III trial. It does not meet the inclusion criteria for an original result report of a drug-containing randomized trial with a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the post-treatment therapeutic effect of tongxie in irritable bowel syndrome: A randomized controlled trial. PMID 35483627 · Complement Ther Med · 2022-Sep The study is not an oncology trial; it investigates a non-drug therapy for irritable bowel syndrome. It does not meet the criteria for human malignant neoplasm, drug intervention, or time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. PMID 35451612 · Eur J Nucl Med Mol Imaging · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants. PMID 35437951 · Clin Pharmacol Drug Dev · 2022-Sep The study is a pharmacokinetic safety study in healthy volunteers, not a randomized controlled trial evaluating a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) in cancer patients. It is not a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and validation of MRI-based radiomics signatures models for prediction of disease-free survival and overall survival in patients with esophageal squamous cell carcinoma. PMID 35384460 · Eur Radiol · 2022-Sep The study is an oncology, human, randomized, original report with time-to-event endpoints (DFS, OS). However, it does not specify a drug-containing intervention (it is a radiomics/modeling study) and does not confirm a Phase III/IIIb or Phase II/III trial. Therefore, it is excluded based on the drug intervention and phase criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cytology-based Cancer Surgery of the Head and Neck (CyCaS-HN): a prospective, randomized, controlled clinical trial. PMID 35305137 · Eur Arch Otorhinolaryngol · 2022-Sep The record is a randomized controlled trial in head and neck cancer with time-to-event efficacy endpoints (OS, PFS, DFS) reported, but it is excluded because it is a non-drug-only intervention (surgical/diagnostic procedure) and does not meet the drug-containing intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES). PMID 35296183 · Mult Scler · 2022-Sep The record describes a randomized controlled trial in multiple sclerosis, which is not a cancer (malignant neoplasm). The study lacks a drug intervention and time-to-event efficacy endpoints required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. PMID 35229668 · Mult Scler · 2022-Sep 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L B
旧查询独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. PMID 35210132 · Eur Urol · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study. PMID 35072852 · Eur J Health Econ · 2022-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). PMID 34988975 · Br J Dermatol · 2022-Sep The record is a Phase II RCT assessing feasibility and AK clearance as surrogate biomarkers, not a Phase III/IIIb or Phase II/III trial with a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Old and Depressed? What We Think About Ending Their Suffering-Attitudes Toward Euthanasia for Elderly Suffering From Physical Versus Mental Illness. PMID 32962531 · Omega (Westport) · 2022-Sep The study is not about a human malignant neoplasm (oncology); it is a randomized survey study on attitudes toward euthanasia for physical vs. mental illness. It has no drug intervention and no time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anastomotic leak after minimally invasive anterior resection for rectal cancer with high versus low ligation of the inferior mesenteric artery: a study protocol for a multicentre randomized clinical trial. PMID 36316694 · Trials · 2022-Oct-31 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Minimally invasivE versus open total GAstrectomy (MEGA): study protocol for a multicentre randomised controlled trial (DRKS00025765). PMID 36316075 · BMJ Open · 2022-Oct-31 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
NAVIGATE: improving survival in vulnerable patients with lung cancer through nurse navigation, symptom monitoring and exercise - study protocol for a multicentre randomised controlled trial. PMID 36316074 · BMJ Open · 2022-Oct-31 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE). PMID 36307892 · Trials · 2022-Oct-28 Protocol article for a randomized controlled trial in oncology. It is not a report of original results. The intervention is radiotherapy (SBRT), not a drug-containing regimen. The primary endpoint is 'survival after recurrence' but no time-to-event results (e.g., KM curves, HR) are presented.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
VoiceS: voice quality after transoral CO2 laser surgery versus single vocal cord irradiation for unilateral stage 0 and I glottic larynx cancer-a randomized phase III trial. PMID 36303192 · Trials · 2022-Oct-27 This is a randomized phase III trial in human oncology, but it compares two non-drug interventions (single vocal cord irradiation vs. transoral CO2-laser surgery). The primary endpoint is voice quality (VHI), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Additionally, this is a protocol registration without reported results, making it ineligible.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. PMID 36302890 · NPJ Precis Oncol · 2022-Oct-27 The record describes an ongoing randomized trial in metastatic cancer (oncology, human) with a drug intervention, but it is a protocol/methods report ('ongoing randomized study', 'Outcomes for randomized patients are awaited') with no reported time-to-event efficacy results. The phase is not specified as Phase III or IIIb. It is therefore not an eligible original formal-result report of a Phase III/IIIb trial with a primary/key secondary time-to-event endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. PMID 36214590 · N Engl J Med · 2022-Oct-27 The study is an oncology randomized trial of a screening intervention (colonoscopy invitation) with cancer incidence and mortality endpoints. It is not a drug intervention and does not report time-to-event efficacy endpoints as required (e.g., OS, PFS, DFS with Kaplan-Meier curves or HRs). The endpoints are 10-year cumulative risks/risk ratios, not time-to-event analyses.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials. PMID 36289451 · BMC Med Res Methodol · 2022-Oct-26 The record is a methods paper presenting a novel Phase II trial design for co-primary endpoints in heterogeneous oncology populations. It is not a report of results from a completed randomized Phase III/IIIb or Phase II/III trial with a drug intervention and a time-to-event efficacy endpoint. Key exclusions: not a Phase III/IIIb trial, not an original result report (it's a design/methodology paper), and no drug intervention or time-to-event endpoint is established.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma. PMID 36288835 · BMJ Open · 2022-Oct-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. PMID 36288281 · Sci Transl Med · 2022-Oct-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease. PMID 36274163 · J Hematol Oncol · 2022-Oct-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparison of different concentrations of a povidone iodine-diluted sitz bath in the prevention of perianal infection in patients undergoing chemotherapy for hematological malignancy: study protocol for a randomized controlled trial. PMID 36273160 · Trials · 2022-Oct-22 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Analgesic efficacy of the bilateral erector spinae plane block for colorectal surgery: a randomized controlled trial. PMID 37386681 · J Anesth Analg Crit Care · 2022-Oct-21 The study is a randomized controlled trial in colorectal cancer surgery patients (oncology, human), but it evaluates an erector spinae plane block (regional anesthesia) for postoperative pain management. It does not include a drug-containing intervention (systemic/cancer drug) as the primary intervention. The primary and secondary endpoints are not time-to-event efficacy outcomes (e.g., OS, PFS) but are analgesic consumption, pain scores, and recovery metrics. No Kaplan-Meier or HR results are reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma. PMID 36271420 · J Hematol Oncol · 2022-Oct-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluation design of the patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard (InAdvance): a randomised controlled trial. PMID 36271332 · BMC Geriatr · 2022-Oct-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Clonal Hematopoiesis in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction. PMID 36229091 · J Am Coll Cardiol · 2022-Oct-18 This is a randomized, primary analysis of a trial (CULPRIT-SHOCK) in acute myocardial infarction and cardiogenic shock, which is a cardiovascular condition, not oncology. While it is a randomized trial with a primary outcome, the intervention is percutaneous coronary intervention (a device/procedure, not a drug), and the primary endpoint is a composite of all-cause mortality or renal replacement therapy at 30 days, reported as odds ratios, not a time-to-event analysis with Kaplan-Meier or hazard ratios. Therefore, it fails the core criteria of being an oncology trial with a drug intervention and a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy. PMID 36229087 · J Am Coll Cardiol · 2022-Oct-18 The study is a randomized trial from SPRINT (Systolic Blood Pressure Intervention Trial) that reports time-to-event outcomes, but it is not an oncology study focused on malignant neoplasms. The intervention is intensive blood pressure lowering using antihypertensive agents, which is a cardiovascular intervention, not a specific oncologic drug therapy. The primary endpoint is a composite of acute decompensated heart failure and death, not a cancer-specific efficacy endpoint like OS, PFS, or DFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Lifestyle interventions after colorectal cancer surgery using a mobile digital device: A study protocol for a randomized controlled trial. PMID 36254015 · Medicine (Baltimore) · 2022-Oct-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparison of whole brain radiation therapy for synchronous brain metastases with irradiation protecting the hippocampus versus whole brain radiotherapy for sequential brain metastases to boost irradiation in the treatment of brain metastases from SCLC: study protocol for a randomized controlled trial. PMID 36242060 · Trials · 2022-Oct-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Outcomes from integrating anti-cervical cancer teachings into the curriculum of high schools in a South-Eastern Nigerian State. PMID 36241979 · BMC Public Health · 2022-Oct-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: randomized clinical trial. PMID 35986684 · Br J Surg · 2022-Oct-14 The trial is a randomized, human oncology study with original results, but it is ineligible because the primary intervention is procedural (stenting vs. surgery) and lacks a drug-containing arm as a key component of the comparison, and the reported efficacy endpoints do not meet the strict time-to-event (e.g., OS, PFS) criteria with KM/HR evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SPONGE-assisted versus Trendelenburg position surgery in laparoscopic sigmoid and rectal cancer surgery (SPONGE trial): randomized clinical trial. PMID 35909251 · Br J Surg · 2022-Oct-14 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial. PMID 36227615 · JAMA Oncol · 2022-Oct-13 The record meets all eligibility criteria: it is an original result report of a randomized oncology trial in humans with a drug intervention (capecitabine) and a primary time-to-event efficacy endpoint (failure-free survival, reported with Kaplan-Meier data and hazard ratio). While the explicit phase (III/IIIb or II/III) is not labeled in the provided metadata, the trial design (open-label RCT, large sample size, definitive comparison of adjuvant therapy vs. observation in locally advanced disease, with 3+ years follow-up and primary efficacy endpoint) is consistent with a Phase III-level definitive trial in oncology. The deterministic review flagged phase evidence as unclear, but the contextual evidence strongly supports phase3_or_definitive as true.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible
Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis. PMID 36227613 · JAMA Oncol · 2022-Oct-13 This is a systematic review and meta-analysis focused on the incidence of cutaneous adverse events (a safety outcome), not an original trial report of a randomized Phase III/IIIb or Phase II/III trial with a primary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized comparison of atrioventricular node re-entry tachycardia and atrial flutter catheter ablation with and without fluoroscopic guidance: ZeroFluoro study. PMID 35979596 · Europace · 2022-Oct-13 This is a randomized controlled trial in interventional cardiology for arrhythmias (SVT, atrial flutter), not oncology. The intervention is a procedural technique (catheter ablation with or without fluoroscopic guidance), not a drug. The primary endpoints are procedural parameters (fluoroscopy time, dose, success rate, recurrence), not time-to-event efficacy endpoints like OS/PFS. Therefore, it does not meet the eligibility criteria for an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized Clinical Trial of Human Papillomavirus Test-and-Treat as Compared to Cytology-Based Screening for Prevention of Cervical Cancer Among Women With Human Immunodeficiency Virus: AIDS Clinical Trials Group Protocol A5282. PMID 35294524 · Clin Infect Dis · 2022-Oct-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -